Oxeia Pioneering First Potential FDA-Approved Concussion Treatment, Launches Equity Crowdfunding Campaign to Fund Phase 2b Development
PR Newswire —
Biotech showed 85% patient improvement in Phase 2a trial—zero approved treatments exist for persistent concussion symptoms BOSTON, Jan. 7, 2026 /PRNewswire/ -- Oxeia Biopharmaceuticals today launched an equity crowdfunding campaign on StartEngine to advance OXE103, a therapy for...